Type 2 diabetes mellitus is a chronic, progressive disease affecting many millions of people worldwide. It carries a great burden of morbidity and premature mortality for the individual, and places great demands on healthcare systems and resources. We now know from clinical studies that improved control of Type 2 diabetes can to some degree reduce its burden. We also know that in the context of a clinical trial, the treatments available to us can do much to improve control in many patients (although all will fall short of`normality'). International guidelines for management of Type 2 diabetes, quite correctly, encourage us to strive for levels of control where we believe the risk of complications is lowest. But is this happening in everyday practice? Data from a survey in three countries show that there is a great difference between the theory of diabetes care and the reality of clinical practice, with levels of glycaemic control in most patients falling short of desired levels. A consideration of the pathophysiology of Type 2 diabetes reveals that it is a complex syndrome focussing on the progressive failure of the pancreatic beta-cell. By acknowledging this fact, and addressing our therapeutic efforts appropriately, we may help to span the gap between theory and reality.
Type 2 diabetes: increasing in prevalence worldwide
Worldwide prevalence of Type 2 diabetes in 1997 stood at approximately 110 million. This ®gure is increasing the world over, and by 2010 projected ®gures suggest almost epidemic growth. While the developing world, particularly Africa and Latin America will bear the brunt and see the greatest proportional increase, Europe is not spared with a probable 50% increase in numbers. 1 Diabetes is a disease with extensive human and economic costs and the consequences of this explosion are profound.
Poor glycaemic control increases long-term complications
Consistently elevated glucose levels increase the risk of development and progression of microvascular and macrovascular disease and hasten disability and death from these causes. Microvascular complications Ð retinopathy, nephropathy and neuropathy Ð are frequently present at the time of diagnosis and progress with disease duration and poor glycaemic control. The 10-y follow-up of the Munich General Practitioner Project found deaths from macrovascular disease to be associated with high lifetime fasting glucose levels and HbA 1c , and those who died from these causes had poorer knowledge about diabetes and its treatment than the survivors. 2 In a striking 7-y cohort study, Haffner and colleagues found the rate of myocardial infarction (MI) in diabetic patients without previous MI to equal that of non-diabetic patients with a previous MI. 3 
Intensive treatment improves prognosis
Fortunately we can, at least to some degree, limit the long-term consequences of diabetes through improved glycaemic control. Data from large epidemiological studies have proven that intensive treatment of diabetes, partly by limiting excessive blood glucose excursions, reduces morbidity. 4 ± 7 As in the equivalent Type 1 diabetes study, the Diabetes Control and Complications Trial (DCCT), 4 reductions in diabetes-related deaths have also been observed but have generally failed to reach statistical signi®cance.
The United Kingdom Prospective Diabetes Study (UKPDS), which collected data from over 5000 Type 2 patients over 10-y, demonstrated a 12% reduction in any diabetes-related endpoint following reduction of HbA 1c from 7.9% to 7.0% through intensive blood glucose control. Microvascular endpoints, including retinopathy requiring photocoagulation, vitreous haemorrhage and renal failure, were reduced by a heart-ening 25% (P 0.0099), with a 16% reduction in MI, marginally failing to reach statistical signi®cance. 6 The Kumamoto study 5 showed a strong relationship between tight metabolic control and reduced progression of nephropathy and retinopathy. As yet unpublished epidemiological analysis of the UKPDS data show a linear relationship between metabolic control and microvascular and macrovascular complications, suggesting that even a small improvement in glycaemic control can offer a prognostic advantage for patients.
Guidelines for risk assessment
So, if tighter glycaemic control improves outcome, are there currently speci®c blood glucose targets that physicians should be aiming to help patients meet? Not any more! Recently, the International Diabetes Federation (IDF) 8 replaced such`targets' with`risk assessment levels', associations between various parameters of metabolic control and degree of risk for adverse outcomes (Table 1) . Perhaps a surprise to some, postprandial glucose level (2 h post-glucose load) features as one parameter of metabolic control, along with the more familiar HbA 1c and fasting glucose level.
The IDF recommends that these assessment levels are used to guide diabetes care, complementing the decision-making process and involving the patient in setting personal goals. They can be used as an educational tool to help patients understand the need for strict metabolic control.
These risk assessment levels also have a role in guiding decisions about when to step up intervention in order to tighten control. With an awareness of risk in mind, physicians and patients can agree mutually acceptable targets for glycaemic control. Progress can then be evaluated during consultations and the questions asked,`Have we reached our agreed target for control? What more could be done to improve control without compromising quality of life?' Are we winning or losing? The gap between theory and practice
The theory and the practice Ð how close are they in reality? Data on actual levels of metabolic control, collected via the NovoNet project, clearly demonstrate that the majority of patients in everyday clinical practice are at risk of micro-and macrovascular complications and require signi®cant reductions in glucose levels. Data from three countries consistently show modal HbA 1c to be 7 ± 8% (borderline for microand macrovascular risk) and more than 60% of patients with Type 2 diabetes to have HbA 1c b 7.5%, a level that is identi®ed by the IDF as carrying increased risk of both macro-and microvascular complications. There is a large and unacceptable gap between theory and practice ( Figure 1 ).
Understanding diabetes pathophysiology
In order to design newer, more effective treatments to address poor metabolic control, a ®rm understanding of diabetic pathophysiology is crucial. It is widely accepted that two pathologies contribute to the development of diabetes: beta-cell failure and insulin resistance. While there is some debate over the relative importance of these in the genesis of Type 2 diabetes, it is clear that the progressive nature of the disease largely re¯ects ongoing beta-cell failure. A decline in beta-cell function is seen in patients with Type 2 diabetes, whereas insulin sensitivity remains unchanged over time (Figure 2 ). While insulin resistance is a contributory factor to poor metabolic control Ð and can be lessened by weight loss to the bene®t of patients Ð the key defect responsible for progression of disease is not insulin resistance but beta-cell failure. 9 The fundamental defect in Type 2 diabetes is in the pattern of insulin secretion. In health, insulin has a Bridging the gap between theory and practice M Nattrass pulsatile meal-related secretory pattern. Obese, nondiabetic patients show a similar pattern but maintain elevated levels of insulin secretion between meals and show excessive prandial insulin peaks. In Type 2 diabetes, basal secretion of insulin is unaffected but mealtime secretion is blunted and delayed, highlighting the mealtime component as the key pathological event. 10 As Type 2 diabetes progresses, the defective prandial insulin response becomes increasingly attenuated.
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Data show that the risk of developing diabetes in obese adults is reduced by sustained weight loss. 12 Compared with a reference group who maintained the same weight over the 16 y period, subjects with sustained weight loss had a 37% lower risk (relative risk 0.63) of developing diabetes. The greatest risk reduction was seen in those who lost weight continually throughout the study, reducing their relative risk to 0.45. The bene®ts were greatest in those who lost more than 6.8 kg (51% risk reduction) and those who started with greater body mass index ( b 29 kgam 2 ). Studies show that weight loss in people who already have diabetes reduces overall insulin secretion because insulin sensitivity is restored. This mirrors the phenomenon seen in obese non-diabetic patients whose basal insulin secretion normalises once they lose weight. Unfortunately, the normal mealtime pattern of insulin secretion is not restored by weight loss in subjects who already have diabetes. 13 
Rational treatment strategies address diabetes pathophysiology
Since the primary pathology in Type 2 diabetes relates to a delayed, blunted insulin response to a glucose load and a progressive reduction in prandial insulin secretion over time, targeting these physiological defects is a rational approach to drug treatment.
Prandial glucose regulation is a novel treatment strategy that speci®cally targets the prandial insulin defect in Type 2 diabetes. By recreating the physiological insulin pro®le, prandial glucose regulation restores the natural rhythm and amplitude of insulin production, affording bene®ts to patients not only in terms of lifestyle but also in improved metabolic control. By relating the treatment to meals it becomes possible for lifestyle to determine treatment rather than vice versa. The demanding requirement to eat regularly and consume interim snacks is abolished and the`one meal, one dose' maxim frees the patient to take medication when it is truly needed, which reduces between-meal and nocturnal hypoglycaemia. This logical approach to treatment maintains strict glycaemic control but not at the cost of quality of life.
These two priorities Ð to improve levels of metabolic control and to enhance quality of life Ð are themes that must simultaneously guide development of future therapies in order for the theory of ®rst-class diabetic care to become a reality.
